u/nadia_norgaard

The fatigue profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression.

non-scale victories count and they are the ones people remember

Nothing on this board is medical advice, and rate, target and method are questions for somebody who knows your history.

a lot of the confident posting here is extrapolation

Adding the standing caveat: none of this is approved anywhere and research material is not for human use.

Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it. Fewer results means wider uncertainty, not a verdict.

Do you have the transaction hash?

Brought the whole CGM export to my appointment rather than one number. Entirely different conversation.

Yes — the person managing your diabetes is the one to talk to, and this board is explicit about that.

Nothing on this board is medical advice, and rate, target and method are questions for somebody who knows your history.

Agreed — measurements over photographs, every time, for anybody trying to actually track something.

Incretin-based agents stimulate insulin secretion in a glucose-dependent manner, which is why hypoglycaemia risk with them alone is low. Risk rises with agents that act independently of glycaemia.

Gently disagree with the framing — that is not a plateau, that is a month. They are different things.

the clothes change before the number does

a single high reading is not a trend

research-use-only material is not approved for human use, full stop

A token symbol identifies an asset, not a network. The same symbol commonly exists on several chains with incompatible address formats, and sending across that boundary is generally unrecoverable.

dose escalation in the trials was slow for a reason

Has anyone posted an independent test on this compound recently?